China-based Suzhou Ribo Life Science Co., Ltd announced that its siRNA drug RBD2080 has received clinical trial approval from Australia’s Therapeutic Goods Administration (TGA). The drug, designed to treat autoimmune diseases, will soon enter a Phase I study in Australia.
Trial Details
The upcoming trial is a randomized, double-blind, placebo-controlled study to assess RBD2080’s safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects.
Drug Profile
Developed using Ribo’s RIBO GalSTAR liver-targeting technology, RBD2080 precisely targets genes linked to autoimmune diseases, offering advantages like accurate targeting and sustained efficacy. The drug aims to provide improved treatment options for patients.-Fineline Info & Tech
